Stuart Therapeutics Submitted FDA Drug Application
The company seeks to study its ST-100 treatment for healing corneal wounds in patients.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Should medical research focus more on repairing damaged biological tissue than providing supportive symptom relief?
Stuart Therapeutics has submitted an investigational new drug application amendment to the FDA for its ST-100 candidate. The drug is designed to repair damaged helical collagen in the eye to support healing.
Why it matters
Current medical treatments for corneal wounds primarily support the eye without addressing the underlying collagen damage, leaving a significant need for regenerative therapies.
ST-100 is engineered to selectively repair damaged helical collagen within the eye to support both epithelial and stromal healing. The technology platform currently utilizes a library of 400 available CMP sequences.
The players
Stuart Therapeutics
A biotechnology company headquartered in Stuart, Florida, that focuses on developing therapies for ocular diseases using collagen-based technology.
FDA
The United States Food and Drug Administration is the federal agency responsible for overseeing the safety and efficacy of new drug applications.
The details
The upcoming proof-of-concept study will investigate how the treatment addresses ocular trauma by focusing on collagen restoration. This application follows previous trial data for dry eye disease that involved over 250 patients and showed improvement in corneal fluorescein staining as early as day 2.
Timeline
October 9, 2026: The company submitted the investigational new drug application amendment.
Early 2027: Stuart Therapeutics expects to begin a phase 3 registration trial for dry eye disease.
Second half of 2027: The company plans to conduct a phase 2 trial for corneal wounds.
The Tech Race
This development highlights the ongoing shift toward regenerative medicine in the biotech sector, where firms are moving beyond simple symptom management to targeted tissue repair. This approach positions Stuart Therapeutics against established players focused on traditional ophthalmic treatments.
The potential clinical success of ST-100 could offer new therapeutic options for the 500,000 Americans who suffer from corneal wounds annually. Patients currently rely on treatments that only support the eye, so this advancement may lead to more effective long-term healing outcomes.
The takeaway
Advancements in collagen-repair technology suggest that the future of ophthalmology may increasingly rely on regenerative medicine to fix structural eye damage. Patients should discuss new treatment modalities with their providers as phase 2 data becomes available in future years.
What happens next
Stuart Therapeutics plans to begin a phase 3 registration trial for dry eye disease in early 2027 and a phase 2 trial for corneal wounds in the second half of 2027.
Further reading
For more information on the evolving landscape of regenerative medicine, visit the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should medical research focus more on repairing damaged biological tissue than providing supportive symptom relief?
